Table of Contents

A patent portfolio analysis Lausanne teams commission turns on one fact international counsel repeatedly get wrong: Switzerland is not in the European Union, not in the Unified Patent Court and not part of the unitary patent, even though it is a founding member of the European Patent Convention. A Lausanne estate therefore has to be mapped as its own territory, reached either by a national Swiss patent or by a European patent validated in Switzerland โ and the national route grants without examining novelty at all. Layer that onto EPFL’s medtech, robotics and life-science output in the heart of Switzerland’s Health Valley, and the analysis has to test strength, isolate the Swiss leg, and prove ownership before the portfolio can be valued.
Why Lausanne portfolios are EPFL and Health Valley built
Lausanne’s IP density is driven by EPFL, one of Europe’s top technical universities, and by its position at the centre of Switzerland’s Health Valley along the Lake Geneva arc. EPFL hosts hundreds of laboratories and the EPFL Innovation Park on campus, and it produces a steady stream of spin-outs โ on the order of twenty to thirty life-science and medtech companies a year โ concentrated in medical devices, robotics, photonics, bioengineering and digital health.
The wider canton of Vaud reinforces this with platforms such as Biopรดle, the life-sciences campus backed by the canton, giving Lausanne one of the densest medtech and drug-discovery ecosystems in Europe. These portfolios are device structures, formulations, diagnostics, surgical robotics and software-driven health tools โ assets whose value is tightly bound to regulatory timing and to a crowded landscape of upstream rights.
That profile shapes the review. Value sits in a few core families, those families usually need protection far beyond Switzerland, and the commercial plan is global from day one. The analysis has to find the assets strong enough to anchor an international programme while handling the Swiss home jurisdiction on its own distinctive terms.
Switzerland is outside the EU, the UPC and the unitary patent
The defining feature of a Swiss portfolio is what it is not part of. Switzerland is a European Patent Convention member, so a European patent granted by the EPO can be validated in Switzerland โ but Switzerland is outside the European Union, and therefore outside both the unitary patent and the Unified Patent Court. The unitary patent does not cover Switzerland, and the UPC has no jurisdiction over Swiss rights.
For a Lausanne company this has direct consequences. A European filing programme that relies on the unitary patent to sweep up the continent in one right leaves a Swiss-shaped hole that has to be filled separately, by validating the European patent in Switzerland or by a national Swiss filing. We check that the Swiss leg of every important family is actually secured, because it is exactly the territory a continental-minded programme forgets.
There is a neat efficiency on the Swiss side: a single Swiss patent right covers both Switzerland and Liechtenstein, which form a unified protection territory under a bilateral treaty. The analysis treats that pairing as one unit, so a Lausanne estate’s home coverage is read correctly rather than as a gap.
Patent portfolio analysis Lausanne needs: the unexamined Swiss patent
The second Swiss peculiarity is how national patents are granted. The Swiss Federal Institute of Intellectual Property (IPI) examines a national patent application for compliance with formal and technical requirements, but it does not examine for novelty or inventive step. In other words, a Swiss national patent can be granted without any assessment of whether the invention is actually new โ those tests only arise if the patent is later litigated.
So a patent portfolio analysis Lausanne founders can rely on never reads a Swiss national grant as proof of validity. We test these rights against the prior art ourselves and flag which families would be vulnerable the moment they were enforced, because a medtech or robotics company that mistakes a Swiss grant for a validated right can badly over-state its moat to an investor or acquirer.
This is also a changing picture. Switzerland has passed a Patent Act reform that will introduce a search on the state of the art for every application and let applicants request a full examination of all patentability requirements, including novelty and inventive step. Until that reform is fully in force, the no-novelty-examination rule stands, and a current analysis is written to it.
Medtech, robotics and life-science estates in Health Valley
No sector defines Lausanne like health technology, and these estates carry issues a generalist review will miss. A medical device or therapeutic sits in a dense thicket of upstream platform patents, so freedom to operate often matters more than the company’s own filings: the question is not only what the company owns but what could block it. We read the estate for both, and flag where an in-licence or a targeted invalidity search is the higher-value next step.
Term and regulatory timing are the second theme. A pharmaceutical patent can be extended in Switzerland by a supplementary protection certificate to offset regulatory delay, and the real exclusivity runway of a life-science estate often turns on whether those certificates are in place, correctly dated and coordinated with the equivalent EU rights. An analysis that ignores SPC term will mis-state the value.
Collaboration is the third. Much Lausanne work is born out of EPFL laboratories, CHUV-linked clinical research, or EU and Innosuisse-funded consortia, and arrives with joint-ownership and background-IP clauses that decide who may license and enforce what. A family the company cannot unilaterally assert is not the asset it appears to be, so we trace those ownership chains before ranking anything.
Where a Swiss patent is enforced: the Federal Patent Court in St. Gallen
Switzerland’s enforcement forum is as distinctive as its grant system. The Federal Patent Court (Bundespatentgericht / Tribunal fรฉdรฉral des brevets), seated in St. Gallen, has exclusive first-instance jurisdiction over patent infringement and validity disputes for the whole of Switzerland, with technically and legally qualified judges and appeals to the Federal Supreme Court. There is no patchwork of cantonal patent courts to navigate.
For a Lausanne portfolio that means a single, specialised national venue โ and, crucially, one that sits entirely outside the UPC. A Swiss family cannot be swept into a UPC central-revocation action the way a non-opted-out European patent can; its fate is decided in St. Gallen under Swiss law. For some estates that insulation is an advantage worth preserving; for others it is simply a separate front to manage.
The patent reform also routes appeals against IPI decisions directly to the Federal Patent Court, consolidating Swiss patent disputes further. Knowing that each Swiss right points to St. Gallen, while its European siblings may point to the UPC, is part of an honest strength read, and the analysis records which forum each asset answers to.
How we work with EPFL spin-outs and Romandie counsel
Most Lausanne work reaches us from a medtech or life-science founder, an EPFL technology-transfer contact, or foreign counsel coordinating a global programme with a Swiss component. All start the same way: with the family tree of the estate and a clear read of where each asset sits across national Swiss rights, validated European patents and โ everywhere outside Switzerland โ the unitary and national systems the Swiss rights do not belong to.
The deliverable is a landscape, gap and strength analysis written for decisions, not for the file. It states plainly which families are unexamined Swiss national grants that have never been tested, which are European patents validated in Switzerland, where the Swiss-and-Liechtenstein home territory is secured, where SPC term extends the runway, and where chain of title from EPFL or a consortium needs proving before a round or a deal.
We work in the languages of Romandie and plug into the client’s existing Swiss and European counsel rather than duplicate them, keeping the output practical enough to sit beside a grant report or a diligence data room. It names the decisions due in the next cycle โ Swiss validations, SPC filings, UPC opt-out choices on the European siblings, assignment clean-ups โ and ranks them by what they protect.
Where a decision turns on facts we cannot settle from the docket alone, such as whether an unexamined Swiss family would survive a novelty attack in St. Gallen or whether a blocking patent threatens freedom to operate in a crowded medtech field, we scope that deeper search plainly rather than let a Swiss grant stand in for a validity opinion.
IP Landscape & Resources in Lausanne
Key intellectual-property authorities and venues relevant to Lausanne:
- Swiss Federal Institute of Intellectual Property (IPI) — grants national Swiss patents, examining formal and technical requirements but not novelty or inventive step
- Swiss Federal Patent Court (Bundespatentgericht), St. Gallen — the exclusive first-instance court for Swiss patent infringement and validity disputes, sitting outside the UPC
- European Patent Office (EPO) — grants European patents that can be validated in Switzerland; the unitary patent does not cover Switzerland
- EPFL โ technology transfer and innovation — the research and spin-out engine behind most of Lausanne's medtech, robotics and life-science patent estates
Request a Patent Portfolio Analysis Consultation in Lausanne
Request a Patent Portfolio Analysis Consultation in Lausanne
Send us your family list and what you believe is protected. We will test your unexamined Swiss national patents against the prior art, confirm the Swiss-and-Liechtenstein leg your continental programme may have missed, map SPC term and UPC opt-out choices on the European siblings, prove chain of title from EPFL or your consortium, and deliver a landscape, gap and strength read built for Lausanne’s Health Valley before any work begins.
Explore related PerspireIP services: Patent Portfolio Analysis · freedom-to-operate and patent infringement analysis · IP market research.
Frequently Asked Questions
Does the unitary patent or the UPC cover a Lausanne company’s Swiss rights?
No. Switzerland is a European Patent Convention member but is outside the European Union, the unitary patent and the Unified Patent Court. A European patent can be validated in Switzerland, but the unitary patent does not reach Swiss territory and the UPC has no jurisdiction over Swiss rights. A continental filing programme that leans on the unitary patent leaves a Swiss-shaped hole, so a patent portfolio analysis checks that the Swiss leg of every important family is separately secured โ remembering that one Swiss right covers both Switzerland and Liechtenstein.
Our Swiss patents are granted โ are they valid?
A Swiss grant is not a validity ruling. The Swiss Federal Institute of Intellectual Property examines a national application for formal and technical compliance but not for novelty or inventive step, so a Swiss national patent can be granted without any assessment of whether the invention is new. Those tests only arise in litigation. We read your Swiss families for genuine strength against the prior art rather than trusting the grant โ relevant while the no-novelty-examination rule stands, ahead of the reform introducing a mandatory search and optional full examination.
Where would a patent dispute involving a Lausanne company be heard?
In the Federal Patent Court (Bundespatentgericht / Tribunal fรฉdรฉral des brevets) in St. Gallen, which has exclusive first-instance jurisdiction over patent infringement and validity for all of Switzerland, with appeals to the Federal Supreme Court. Because Switzerland sits outside the UPC, a Swiss right cannot be pulled into a UPC central-revocation action the way a non-opted-out European patent can. The analysis records which forum each asset answers to, since a family’s Swiss and European siblings may point to different courts.
Why does SPC term and chain of title matter for an EPFL spin-out portfolio?
Both drive real value. For life-science families, a supplementary protection certificate can extend a Swiss patent to offset regulatory delay, so the true exclusivity runway often depends on whether SPCs are in place, correctly dated and coordinated with the EU equivalents. And because many Lausanne estates come out of EPFL laboratories, CHUV-linked research or funded consortia, they carry joint-ownership and background-IP clauses. The analysis proves the chain of title and confirms the company can unilaterally license and enforce each family before any valuation is placed on it.